NEW YORK and LONDON, September 16th, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced that Dr. …

[Read more...] about Akari Therapeutics to Present at Upcoming Investor Conferences on September 27 and 28 in New York City

NEW YORK and LONDON, September 12th, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …

[Read more...] about Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria

NEW YORK and LONDON, August 4th, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that …

[Read more...] about Akari Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference